@article{721005,
      recid = {721005},
      author = {Nicholson, Anna,},
      title = {Developing and strengthening the global supply chain for  second-line drugs for multidrug-resistant tuberculosis  workshop summary / [electronic resource] :. Workshop on  Developing and Strengthening the Global Supply Chain for  Second-Line Drugs for Multidrug-Resistant TB},
      pages = {1 online resource (170 pages) :},
      note = {"Forum on drug discovery, development, and  translation."--Cover.},
      abstract = {To effectively treat patients diagnosed with  drug-resistant (DR) tuberculosis (TB) and protect the  population from further transmission of this infectious  disease, an uninterrupted supply of quality-assured (QA),  second-line anti-TB drugs (SLDs) is necessary. Patients  diagnosed with multidrug-resistant tuberculosis (MDR TB) a  disease caused by strains of Mycobacterium tuberculosis  (M.tb.) resistant to two primary TB drugs (isoniazid and  rifampicin) face lengthy treatment regimens of 2 years or  more with daily, directly observed treatment (DOT) with  SLDs that are less potent, more toxic, and more expensive  than those used to treat drug-susceptible TB. From 2000 to  2009, only 0.2-0.5 percent of the estimated 5 million MDR  TB cases globally were treated with drugs of known quality  and in programs capable of delivering appropriate care  (Keshavjee, 2012). The vast majority of MDR TB patients  either died from lack of treatment or contributed to the  spread of MDR TB in their communities. A strengthened  global supply chain for SLDs could save lives by  consistently delivering high quality medicines to more of  the people who need them. This public workshop explored  innovative solutions to the problem of how to get the right  SLDs for MDR TB to people who critically need them. More  specifically, the workshop examined current problems and  potential opportunities for coordinated international  efforts to ensure that a reliable and affordable supply of  high-quality SLDs is available. Developing and  Strengthening the Global Supply Chain for Second-Line Drugs  for Multidrug-Resistant Tuberculosis: Workshop Summary  covers the objectives of the workshop, which were to  review: To what extent and in what ways current mechanisms  are or are not effectively accomplishing what is needed,  including consideration of bottlenecks ; The advantages and  disadvantages of centralization in the management of the  global drug supply chain, and potential decentralized  approaches to improve operations of the supply chain ; What  can be learned from case studies and examples from other  diseases (e.g., the Affordable Medicines Facility-malaria  (AMFm) and the U.S. President's Emergency Plan for AIDS  Relief [PEPFAR]) ; The current allocation of  responsibilities and roles of the private (including  industry and nonprofit public health organizations) and  public sectors, and examination of opportunities for  enhancing and optimizing collaboration ; Identification of  potential innovative solutions to the problem.},
      url = {http://library.usi.edu/record/721005},
}